CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.86B, above the global median of $1.18B
- FinancialsAltman Z-Score 5.63: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
4.54%
Annual Rate
CNY 2.40Paid semi-annual
Payout Ratio
92.8%High
Payback Period
28.9 yr
Last Ex-Dividend
Apr 10, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.46BCNY1.86B · vs all stocks (USD)
Trailing P/E
27.22xvs Medical Devices peers
Revenue (TTM)
3.96BCNY591.45M · vs all stocks (USD)
Profit Margin
10.26%vs Medical Devices peers
Beta
0.6050xvs all stocks
52-Week Change
33.84%vs all stocks
Forward Annual Dividend Yield
4.54%vs all stocks
Market Capitalization
12.46BCNY1.86B · vs all stocks (USD)
Enterprise Value
9.83BCNY1.47B · vs all stocks (USD)
Trailing P/E
27.22xvs Medical Devices peers
Forward P/E
21.15xvs Medical Devices peers
Price to Sales (TTM)
3.14xvs Medical Devices peers
Price to Book (MRQ)
2.10xvs Medical Devices peers
Enterprise to Revenue
2.48xvs Medical Devices peers
Enterprise to EBITDA
19.36xvs Medical Devices peers
Gross Margin
56.59%vs Medical Devices peers
Profit Margin
10.26%vs Medical Devices peers
Operating Margin
8.66%vs Medical Devices peers
Return on Assets (TTM)
3.53%vs Medical Devices peers
Return on Equity (TTM)
7.87%vs Medical Devices peers
Revenue (TTM)
3.96BCNY591.45M · vs all stocks (USD)
Revenue per Share (TTM)
19.04CNYUpdated Sep 20, 2026Quarterly Revenue Growth
39.80%vs Medical Devices peers
Gross Profit (TTM)
2.16BCNY321.61M · vs all stocks (USD)
EBITDA (TTM)
611.23MCNY91.21M · vs all stocks (USD)
Net Income (TTM)
406.48MCNY60.66M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
25.40%vs Medical Devices peers
Operating Cash Flow (TTM)
606.70MCNY90.53M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
332.11MCNY49.56M · vs all stocks (USD)
Forward Annual Dividend Rate
2.40CNYUpdated Sep 20, 2026Forward Annual Dividend Yield
4.54%vs all stocks
Trailing Annual Dividend Rate
1.80CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
3.40%vs all stocks
Payout Ratio
92.78%vs Medical Devices peers
Minority Interest (Equity)
36.03MCNYFY2025 · Dec 31, 2025Revenue
3.39BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.59BCNYFY2025 · Dec 31, 2025Gross Profit
1.80BCNYFY2025 · Dec 31, 2025Operating Income
395.56MCNY59.03M · vs all stocks (USD)
Pre-tax Income
425.84MCNYFY2025 · Dec 31, 2025Income Tax Expense
55.53MCNYFY2025 · Dec 31, 2025Net Income
370.32MCNYFY2025 · Dec 31, 2025EBIT
441.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
611.23MCNYFY2025 · Dec 31, 2025Research & Development
87.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
757.01MCNYFY2025 · Dec 31, 2025Other Operating Expenses
53.46MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
26.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
16.07MCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
370.32MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.29MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
424.46MCNYFY2025 · Dec 31, 2025Free Cash Flow
264.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.29BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
370.32MCNYFY2025 · Dec 31, 2025Other Non-cash Items
43.63MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-20.77MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.28MCNYFY2025 · Dec 31, 2025Capital Expenditures
-159.89MCNYFY2025 · Dec 31, 2025Net Acquisitions
-126.27MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.05BCNYFY2025 · Dec 31, 2025Sale of Investments
2.26BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-68.96MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.16BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.25BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-371.78MCNYFY2025 · Dec 31, 2025Other Financing Charges
-3.72MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-468.75MCNYFY2025 · Dec 31, 2025Shares Outstanding
235.90MSharesUpdated Sep 20, 2026Float Shares
104.67MSharesUpdated Sep 20, 2026% Held by Insiders
57.71%vs all stocks
% Held by Institutions
9.73%vs all stocks
Total Cash (MRQ)
3.06BCNY456.94M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.48CNYUpdated Sep 20, 2026Total Debt (MRQ)
867.65MCNY129.47M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1560xvs Medical Devices peers
Current Ratio (MRQ)
2.63xvs Medical Devices peers
Book Value per Share (MRQ)
25.13CNYUpdated Sep 20, 2026Total Assets
6.63BCNY989.17M · vs all stocks (USD)
Total Current Assets
3.84BCNYFY2025 · Dec 31, 2025Total Liabilities
1.73BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.79BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
137.26MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.59BCNYFY2025 · Dec 31, 2025Cash
1.34BCNYFY2025 · Dec 31, 2025Cash Equivalents
84.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.42BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.02BCNYFY2025 · Dec 31, 2025Accounts Receivable
404.79MCNYFY2025 · Dec 31, 2025Inventory
675.50MCNYFY2025 · Dec 31, 2025Accounts Payable
639.05MCNYFY2025 · Dec 31, 2025Short-term Debt
758.14MCNYFY2025 · Dec 31, 2025Other Current Liabilities
13.77MCNYFY2025 · Dec 31, 2025Long-term Debt
68.04MCNYFY2025 · Dec 31, 2025Common Stock (Book)
208.90MCNYFY2025 · Dec 31, 2025Retained Earnings
769.75MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.90BCNY731.61M · vs all stocks (USD)
Treasury Stock
140.47MCNYFY2025 · Dec 31, 202552-Week Low
37.70CNYUpdated Sep 20, 202652-Week High
63.99CNYUpdated Sep 20, 202652-Week Change
33.84%vs all stocks
Beta
0.6050xvs all stocks
50-Day MA
51.00CNYUpdated Sep 20, 2026200-Day MA
51.77CNYUpdated Sep 20, 2026Avg 10-Day Volume
2.74MSharesUpdated Sep 20, 2026Avg 30-Day Volume
2.30MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
1.94CNYUpdated Sep 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.63: safe zoneNotable
Altman Z-Score: 5.63
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.86B, above the global median of $1.18BNotable
Market cap (USD): 1,858,589,057.952Global Median: 1,180,223,658.953
Revenue is $591.45M, above the global median of $548.88MNotable
Revenue (USD): 591,445,889.879Global Median: 548,883,780.48
Levered free cash flow is $49.56M, above the global median of $18.73MNotable
Levered free cash flow (USD): 49,557,093.684Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Porton Pharma Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novocure Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mabwell (Shanghai) Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cocreation Grass Co. Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Ingenic Semiconductor Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Xiamen Leading Optics Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities